Journal
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 96, Issue 6, Pages 845-853Publisher
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2010.036350
Keywords
JAK; tyrosine kinase; mutations; inhibitors; STAT
Categories
Funding
- Belgian State, Prime Minister's Office, Science Policy Programming
- Actions de Recherche Concertees (ARC) of the Communaute Francaise de Belgique
- Atlantic Philanthropies, New York
- PAI Program [BCHM61B5]
- Belgian American Educational Foundation
- Foundation Salus Sanguinis, Belgium
- operation Televie, Belgium
Ask authors/readers for more resources
Background Activating mutations in JAK1 and JAK2 have been described in patients with various hematologic malignancies including acute lymphoblastic leukemia and myeloproliferative neoplasms, leading to clinical trials with JAK inhibitors. While there has been a tremendous effort towards the development of specific JAK inhibitors, mutations conferring resistance to such drugs have not yet been observed. Design and Methods Taking advantage of a model of spontaneous cellular transformation, we sequenced JAK1 in selected tumorigenic BaF3 clones and identified 25 de novo JAK1 activating mutations, including 5 mutations already described in human leukemias. We further used this library of JAK1 mutation-positive cell lines to assess their sensitivity to ATP-competitive inhibitors. Results While most JAK1 mutants were sensitive to ATP-competitive JAK inhibitors, mutations targeting Phe958 and Pro960 in the hinge region of the kinase domain rendered JAK1 constitutively active but also resistant to all tested JAK inhibitors. Furthermore, mutation of the homologous Tyr931 in JAK2 wild-type or JAK2 V617F mutant found in patients with myeloproliferative neoplasms also conferred resistance to JAK inhibitors, such as INCB018424, which is currently in clinical use. Conclusions Our data indicate that some activating mutations not only promote autonomous cell proliferation but also confer resistance to ATP-competitive inhibitors. In vivo, such a mutation can potentially occur as primary JAK-activating mutations but also as secondary mutations combining oncogenicity with drug resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available